NCT05434689View on ClinicalTrials.gov

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Iberdomide

Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.

DRUG

Daratumumab

Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma

DRUG

Dexamethasone

Corticosteroid active against multiple myeloma in combination with other agents

DRUG

Carfilzomib

Second generation proteasome inhibitor with activity in multiple myeloma

Trial Locations (6)

27710

NOT_YET_RECRUITING

Duke University, Durham

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

37232

NOT_YET_RECRUITING

Vanderbilt University Medical College, Nashville

43210

RECRUITING

Ohio State University Medical College, Columbus

53705

RECRUITING

University of Wisconsin, Madison

97239

RECRUITING

Oregon Health and Science University, Portland

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

coMMit Myeloma Trials

UNKNOWN

lead

University of Alabama at Birmingham

OTHER